Amarin Corp Plc (AMRN)

[bfost]

KIWI - Good question. I think there are a few reasons.
1. Clinical inertia - it's easier for docs to do the same thing they've been doing despite potential evidence to the contrary especially with a silent disease process.
2. Patients/docs are not aware of or have trouble navigating the Vascepa savings card program- It took several phone calls and some persistence for me to accomplish this today.
3. Things move very slowly in medicine. 3/4 of my primary care colleagues have never even heard of Vascepa.
4. It will take a brick to the side of the head (+RI in NEJM) to dramatically change things and even then it will take a fair amount of time before it is the defacto standard of care. I could name lot's of things in medicine that are now standard of care that took years to be accepted despite good evidence. Early adopters will drive rx's early but the other 75% will take a while to get on board.

That being said I'm actually a little bit surprised they've been able to have a 27% market share of new scripts.